The ICNC 2016 organisation offers a wide range of sponsoring and exhibiting opportunities.
In order to receive more information and the sponsoring prospectus, please contact us at firstname.lastname@example.org
At Shire, we enable people with life-altering conditions to lead better lives. We focus on developing and delivering innovative medicines for patients with rare diseases and other specialty conditions. This might be a therapy to treat an extremely rare and life-threatening disease such as Hunter syndrome or Fabry disease, or a medicine for a specialist condition such as ADHD or ulcerative colitis.
To realize our aspiration to become a leading global biotech, our efforts are concentrated on four key strategic drivers: growth, innovation, efficiency, and people. Our priorities are to drive optimal performance of our existing products, increase patient access to these medicines, and to build our pipeline through research and development and partnerships in order to deliver new medicines to patients.
PTC Therapeutics is a global biopharmaceutical company focused on the discovery, development and commercialization of novel orally administered drugs that target RNA mechanisms affecting protein production. It is PTC’s mission to bring new therapies to patients affected by rare and neglected diseases such as cystic fibrosis and Duchenne muscular dystrophy. For more information please visit www.ptcbio.com.
Novartis Oncology is a global leader in transforming outcomes for people living with cancer and other diseases. We offer a wide range of innovative therapies to help meet patient needs and our oncology pipeline is one of the strongest and most productive in the industry. Our research is driven by a distinctive scientific and clinical strategy focused on precision oncology – understanding how cancer develops on a genomic level and developing drugs that hone in on those targets. For more information about how we are transforming the treatment of cancer and other diseases, visit www.novartisoncology.com
Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology company and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies.
BIOCODEX is a French independent pharmaceutical company relying on a global network of scientists and partners. This allowing to acquire, over the years, expertise in specific therapeutic areas, such as in orphan disease in children epilepsy, and now enables patients in over 100 countries to have access to its innovative medication. Powered by an industrial vision and innovation, BIOCODEX is committed to provide the best care to patients, emphasizing work on the long term in a constant dialogue with healthcare professionals.
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8500 people in approximately 40 countries, the company generated revenue of € 3.3 billion in 2014. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news